Objective： To investigate the clinical efficacy of Shenshuaiyi,Formula in the treatment of chronic kidney disease （CKD） at stage 4 combined with chronic heart failure （CHF）.,Methods,2,Eighty patients of CKD at stage 4 combined with CHF （spleen and kidney qi deficiency and blood stasis syndrome） were randomly divided into the control group and the treatment group， 40 cases in each group. The patients in the control group were treated with routine western medicine， and the patients in the treatment group were treated with routine western medicine combined with Shenshuaiyi,Formula orally， with a course of 8 weeks. The clinical efficacy of the two groups was evaluated. Before and after treatment， the changes of the total scores of traditional Chinese medicine （TCM） syndrome and the main symptom scores were compared between the two groups， and the levels of serum creatinine （SCr）， urea nitrogen （BUN）， estimated glomerular filtration rate （eGFR）， tumor necrosis factor-α （TNF-α）， interleukin-6 （IL-6）， hypersensitive C-reactive protein （hsCRP） and N-terminal B-type brain natriuretic peptide precursor （NT-proBNP） of all the patietns were detected， the left ventricular ejection fraction （LVEF） was compared between the two groups， and the New York Heart Association （NYHA） cardiac function grading of the patients in the two groups was evaluated.,Results,2,During the course of treatment， 1 patient in the control group was removed and 1 patient in the treatment group was shed off， finally 39 cases in the control group and 39 cases in the treatment group were included in the statistical analysis. ①After treatment， the total clinical effective rate was 84.62% in the treatment group and 56.41% in the control group， and the effect of the treatment group was better than that of the control group （,P,<,0.05）. ②After treatment， the total scores of TCM syndrome in the two groups were significantly decreased （,P,<,0.05）， and the score of the treatment group was lower than that of the control group （,P,<,0.05）. The main symptom scores in the two groups were decreased compared with those before treatment （,P,<,0.05）， and the scores of fatigue， shortness of breath and taciturnity， lack of appetite， and aching and weakness of waist and knee symptoms in the treatment group were lower than those in the control group （,P,<,0.05）. ③After treatment， the levels of SCr， BUN， TNF-α， IL-6， hsCRP and NT-proBNP in the two groups were decreased compared with those before treatment （,P,<,0.05）， the levels of eGFR and LVEF were increased compared with those before treatment （,P,<,0.05）， and the levels of SCr， BUN， TNF-α， IL-6， hsCRP and NT-proBNP in the treatment group were lower than those in the control group （,P,<,0.05）， the levels of eGFR and LVEF were higher than those in the control group （,P,<,0.05）. ④After treatment， the NYHA cardiac function grading of the patients in the two groups was improved （,P,<,0.05）， and the improvement of the treatment group was better than that of the control group （,P,<,0.05）.,Conclusion,2,Shenshuaiyi,Formula combined with conventional western medicine can better improve the renal and cardiac functions of the patients with CKD at stage 4 combined with CHF （spleen and kidney qi deficiency and blood stasis syndrome）， decrease the levels of serum inflammatory factors， and enhance the clinical efficacy.